Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

RITE AID EXPLORING "ALL LEGAL ALTERNATIVES" to address recent bribery charges against company President Martin Grass, the firm said in a recent statement. The company is assembling documentation supporting its position that Grass' arrest and the bribery charges against him are part of a "long and determined vendetta" against Rite Aid by certain members and associates of the Ohio Board of Pharmacy, according to a company spokesperson. Grass was charged with one count of bribery by the Cuyahoga County Sheriff's office in Cleveland, Ohio after being arrested on April 27. Martin Grass, 35, who was named president of Rite Aid approximately one month ago, retains his position within the company. He was arrested while handing a company check for about $ 30,000 to Melvin Wilczynski, a member of the Ohio Board of Pharmacy and consultant and former employee of Peoples Drug. Rite Aid maintains that the check was a payment made "in exchange for a corporate release settling the consultant agreement prepared by the Rite Aid Corporation legal department and signed by Wilczynski." The consulting agreement between Wilczynski and Peoples became a "legal obligation of Rite Aid" when the firm acquired The Lane Drug Company, a division of Peoples, on April 10, Rite Aid noted. However, according to Cuyahoga County Prosecuting Attorney John Corrigan, the payment was a "bribe" intended to remove Wilczynski from the Ohio board and replace him with "a pharmacist of Rite Aid's choosing." Rite Aid issued a statement May 5 disclosing that members of its management had met with members of the Ohio State Pharmacy Board and a member of the state government on March 28 "to discuss matters related to the administration and enforcement of pharmacy laws in Ohio." The four Rite Aid execs included James Krahulec, VP government affairs and trade relations and Wayne Korte, pharmacy division manager. However, the firm maintains that Krahulec and Korte "have not violated any laws of the state of Ohio at any time." Referring to charges that the company had been trying to load the pharmacy board with friends of Rite Aid, the firm asserted: "Rite Aid Corporation and Martin L. Grass believe that as the facts are thoroughly examined and become public concerning Mr. Grass' alleged actions and the activities by certain associates of the Ohio Pharmacy Board, that Mr. Grass and the corporation will be exonerated. Rite Aid and Mr. Grass deny any wrongful intent and any involvement in any criminal conduct and intend to diligently defend any criminal charges." Rite Aid has been growing rapidly in Ohio in the past few years and now has a total of 349 outlets in the state. Rite Aid acquired 103 stores in Ohio with the Lane Drug purchase. In 1987, the firm added 162 Gray Drug Fair stores in the state to its chain. Shortly after its acquisition of the Gray Drug Fair stores, Rite Aid received citations against 90 stores for security violations. Pharmacists in the stores also received citations. The company paid $ 50,000 in fines in January of 1988 to settle the charges. The company asserted in a May 1 release that the Grass case is not the subject of a federal inquiry. "Contrary to previous statements in the press," the release said: "Rite Aid Corporation . . . today was informed by William J. Edwards, acting U.S. attorney for the northern district of Ohio in Cleveland, Ohio, that there is no federal investigation of any kind underway concerning Rite Aid."

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts